CA2473312C - Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan - Google Patents
Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan Download PDFInfo
- Publication number
- CA2473312C CA2473312C CA2473312A CA2473312A CA2473312C CA 2473312 C CA2473312 C CA 2473312C CA 2473312 A CA2473312 A CA 2473312A CA 2473312 A CA2473312 A CA 2473312A CA 2473312 C CA2473312 C CA 2473312C
- Authority
- CA
- Canada
- Prior art keywords
- carrageenan
- film
- composition
- weight
- kappa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Abstract
A film-forming hydrocolloid composition comprising kappa carrageenan, iota carrageenan, a bulking agent, plasticizer and water is described. The ratio of bulking agent to total carrageenan is from about 1:1 to 20:1. Kappa carrageenan is present in an amount of less than or equal to 50% by weight of total carrageenan present. To form the composition, all dry materials are mixed and added to a heated mixture of all liquid materials. The final mixture is heated until a composition free of particulate materials is formed. The formed composition can be cast or extruded into ribbons, films, sheets, tubes or the like, for encapsulating wet or dry materials including medicinal dosage forms, nutritional supplements, cosmetics, bath oils and gels, and paint balls.
Description
NON-GELATIN CAPSULE SHELL FORMULATION COMPRISING IOTA-CARRAGEENAN AND
KAPPA-CARRAGEENAN
Field of the Invention [001] The present invention relates to the field of film-forming or gel-forming compositions, and more particularly to substitutes for mammalian-based gel forming materials used in the manufacture of softgels and gelcaps.
Background of the Invention
KAPPA-CARRAGEENAN
Field of the Invention [001] The present invention relates to the field of film-forming or gel-forming compositions, and more particularly to substitutes for mammalian-based gel forming materials used in the manufacture of softgels and gelcaps.
Background of the Invention
[002] Gelatin has a wide range of commercial utility. For example, gelatin is used in wet processed photographic emulsions, pharmaceutical dosage forms, cosmetics (binder), and a wide range of food products. Gelatin has many useful physical and chemical properties that support this broad range of utility.
[003] Gelatin is manufactured by the hydrolysis of animal by-products that contain collagen. This is usually found in animal bones, skins, and connective tissue.
The collagen containing material is heated in water and the liquor produced is concentrated and dried, leaving behind the colorless or pale yellow protein that constitutes the hydrophilic colloid material known as gelatin.
The collagen containing material is heated in water and the liquor produced is concentrated and dried, leaving behind the colorless or pale yellow protein that constitutes the hydrophilic colloid material known as gelatin.
[004] The primary sources of gelatin are from bovine and swine animals.
Additionally, fish and poultry are alternative small volume sources of gelatin. The source of gelatin can be a problem for potential areas of use or for particular consumers. Large groups around the world choose not to ingest any products of pigs (e.g., vegetarians, Hebrews, and Muslims) or the products of beef (e.g., vegetarians and Hindus). As medication and/or diet supplements are provided in gelatin capsules without any indication of the source of the gelatin, the use of capsules is restricted in areas where religious beliefs question the source of the gelatin.
Additionally, due to reported possibilities of cross-contamination of diseases among species, for example bovine spongiform encephalopathy ("BSE" or "Mad Cow Disease"), the use of uncontrolled by-products from animals has lost some level of commercial acceptance. In short, there is a need for replacement compositions for gelatin that are not derived from animal sources.
Additionally, fish and poultry are alternative small volume sources of gelatin. The source of gelatin can be a problem for potential areas of use or for particular consumers. Large groups around the world choose not to ingest any products of pigs (e.g., vegetarians, Hebrews, and Muslims) or the products of beef (e.g., vegetarians and Hindus). As medication and/or diet supplements are provided in gelatin capsules without any indication of the source of the gelatin, the use of capsules is restricted in areas where religious beliefs question the source of the gelatin.
Additionally, due to reported possibilities of cross-contamination of diseases among species, for example bovine spongiform encephalopathy ("BSE" or "Mad Cow Disease"), the use of uncontrolled by-products from animals has lost some level of commercial acceptance. In short, there is a need for replacement compositions for gelatin that are not derived from animal sources.
[005] Carrageenan is a natural hydrocolloid, more particularly a polysaccharide hydrocolloid, which is derived from red seaweed, particularly of the species Rhodophycea.
Carrageenan is a carbohydrate polymer of repeating galactose and 3,6-anhydrogalactose (sugar) units that is linear and without significant numbers of branches or substitutions. Most, if not all, of the galactose units on a carrageenan molecule possess a sulfated ester group. The exact position of the sulfate groups, the cations on the sulfate groups, and the possible presence of an anhydrous bridge on the molecule differentiate the various types of carrageenan.
Carrageenan is a carbohydrate polymer of repeating galactose and 3,6-anhydrogalactose (sugar) units that is linear and without significant numbers of branches or substitutions. Most, if not all, of the galactose units on a carrageenan molecule possess a sulfated ester group. The exact position of the sulfate groups, the cations on the sulfate groups, and the possible presence of an anhydrous bridge on the molecule differentiate the various types of carrageenan.
[006] There are five distinct types of carrageenan, each of which behaves differently and has distinct properties. The types of carrageenan are iota, kappa, lambda, mu and nu carrageenan. These types of carrageenan can significantly vary in properties.
For example, lambda carrageenan in solution is unable to associate into a structure, and therefore is unable to form a gel, but nonetheless acts as a thickener. Both kappa and iota carrageenan, the predominant carrageenan types, are able to form gels. Kappa carrageenan is known to form strong gels in the presence of potassium cations. However, kappa carrageenan gels tend to be brittle and exhibit syneresis (exudation of the liquid portion of the gel).
Iota carrageenan tends to react strongly to calcium cations and forms a weaker and more flexible gel than kappa carrageenan. Iota carrageenan is not as susceptible to syneresis as kappa carrageenan. Mu and nu carrageenan are thought to be precursors of kappa carrageenan and iota carrageenan, respectively, and may be present only in very small quantities as impurities in pure kappa and iota carrageenan. Mu and nu carrageenan are not of commercial importance.
For example, lambda carrageenan in solution is unable to associate into a structure, and therefore is unable to form a gel, but nonetheless acts as a thickener. Both kappa and iota carrageenan, the predominant carrageenan types, are able to form gels. Kappa carrageenan is known to form strong gels in the presence of potassium cations. However, kappa carrageenan gels tend to be brittle and exhibit syneresis (exudation of the liquid portion of the gel).
Iota carrageenan tends to react strongly to calcium cations and forms a weaker and more flexible gel than kappa carrageenan. Iota carrageenan is not as susceptible to syneresis as kappa carrageenan. Mu and nu carrageenan are thought to be precursors of kappa carrageenan and iota carrageenan, respectively, and may be present only in very small quantities as impurities in pure kappa and iota carrageenan. Mu and nu carrageenan are not of commercial importance.
[007] The type of carrageenan used affects the physical properties of the final gel or film. WO 99/07347 and WO 01/03677 describe gel forming compositions that have iota carrageenan as the sole gelling agent. Despite the fact that kappa carrageenan is also able to gel, these publications teach that kappa carrageenan is detrimental when the end product desired is a film for capsule manufacture. The phenomenon of syneresis and the fact that kappa carrageenan forms brittle gels are cited as reasons for avoiding the use of kappa carrageenan in such films.
[008] When forming a film for subsequent use in medicinal, cosmetic, or nutritional capsule manufacture, the resultant physical properties of sealability, extensibility, and tensile strength are important. Thus, a gelling composition comprising carrageenan must provide adequate physical properties useful in manufacturing. Kappa carrageenan is a less expensive starting material as compared to iota carrageenan. Thus, it would be beneficial to develop a gel-or film-forming composition comprising kappa carrageenan and iota carrageenan, wherein the resultant film provides the requisite physical properties for capsule manufacture.
Summary of the Invention
Summary of the Invention
[009] The present invention is a non-animal based hydrocolloid film-forming composition for use in the manufacture of encapsulated dosage forms. The film-forming composition comprises:
iota carrageenan in an amount from about 1% to about 15% by weight of the composition;
a bulking agent wherein the ratio of bulking agent:total carrageenan is from at least about 1:1 to about 20:1;
kappa carrageenan in an amount less than or equal to 50% by weight of total carrageenan;
a plasticizer in an amount of from about 10% to about 50% by weight of the total composition; and water to form 100% by weight of the composition, wherein the total of all carrageenan is in an amount less than or equal to 20%
by weight of the composition.
The kappa carrageenan provides gel strength while the iota carrageenan provides flexibility to the film-forming composition.
iota carrageenan in an amount from about 1% to about 15% by weight of the composition;
a bulking agent wherein the ratio of bulking agent:total carrageenan is from at least about 1:1 to about 20:1;
kappa carrageenan in an amount less than or equal to 50% by weight of total carrageenan;
a plasticizer in an amount of from about 10% to about 50% by weight of the total composition; and water to form 100% by weight of the composition, wherein the total of all carrageenan is in an amount less than or equal to 20%
by weight of the composition.
The kappa carrageenan provides gel strength while the iota carrageenan provides flexibility to the film-forming composition.
[10] The composition optionally can include one or more additives as known to practitioners in the art such as an opacifier, preservative, flavorant, colorant and the like.
[011] The composition is formed by mixing iota carrageenan, kappa carrageenan, one or more bulking agents, a plasticizer and water and heating the mixture with stirring until a smooth mixture free of particulates is achieved. Desirably, all dry ingredients, including iota carrageenan, kappa carrageenan and one or more bulking agents are mixed together while all liquid ingredients, including water and plasticizer, are mixed together and heated to at least about 75 C. The dry mix is added to the heated liquid mixture with stirring and further heated to a temperature of no more than about 95 C with stirring until a smooth mixture free of particulates is achieved. Alternatively, the dry mix and liquid mixture can be fed to an extruder where the dry mix and liquid mix are mixed and heated simultaneously into a smooth mixture free of particulates, then extruded through dies.
The invention relates according to an aspect, to a method for preparing a film-forming composition. The method comprises the steps of: a) mixing iota carrageenan in an amount of from about 1% to about 15% by weight of the composition, kappa carrageenan in an amount less than 100% by weight of the iota carrageenan and a bulking agent in a ratio of bulking agent to total carrageenan of from about 1: 1 to about 20:1 to form a dry mixture; b) mixing a plasticizer and water to form a liquid mixture; c) heating the liquid mixture to a temperature of from about 75 C to about 90 C; d) adding the dry mixture to the heated mixture with stirring to form a dispersion; and e) heating the dispersion with stirring to a temperature of from about 85 C to about 95 C to form a uniform dispersion.
The invention relates according to an aspect, to a method for preparing a film-forming composition. The method comprises the steps of: a) mixing iota carrageenan in an amount of from about 1% to about 15% by weight of the composition, kappa carrageenan in an amount less than 100% by weight of the iota carrageenan and a bulking agent in a ratio of bulking agent to total carrageenan of from about 1: 1 to about 20:1 to form a dry mixture; b) mixing a plasticizer and water to form a liquid mixture; c) heating the liquid mixture to a temperature of from about 75 C to about 90 C; d) adding the dry mixture to the heated mixture with stirring to form a dispersion; and e) heating the dispersion with stirring to a temperature of from about 85 C to about 95 C to form a uniform dispersion.
[012] These and other aspects of the present invention as disclosed herein will become apparent to those skilled in the art reading the following description of embodiments of the invention. The embodiments as set forth herein do not limit the scope of the invention, which is intended to cover equivalent materials, methods and compositions as known to practitioners in the art, and as set forth in the appended claims.
4a Detailed Description of Embodiments of the Invention
4a Detailed Description of Embodiments of the Invention
[013] Formulations and methods for the manufacturing of non-animal based hydrocolloid film-forming compositions are described. The film-forming composition is used for encapsulation of dosage forms in liquid, solid, gel, paste or suspension form. Such dosage forms can include medicinal, pharmaceutical, nutritional or dietetic drug dosage forms, as well as cosmetics, paints, bath products or other desirably encapsulated dosage forms.
[014] As used herein, the term "softgel" means a soft gelatin capsule, in agreement with the accepted nomenclature adopted by the SoftGel Association. Formerly, the accepted nomenclature was a soft elastic gelatin (SEG) capsule. Generally, a softgel is a one-piece, sealed, soft gelatin (or other film-forming material) shell that contains a solution, a suspension, or a semi-solid paste.
[015] Other encapsulated dosage forms are known to practitioners in the art and include, but are not limited to, caplets such as SOFLETTM gelatin-enrobed hard tablets made by Banner Pharmacaps, Inc.
[016] The phrase "dosage form" as used herein encompasses any material or composition in a form suitable for encapsulation by the film-forming composition described herein. Thus, a dosage form can be a pharmaceutical or nutritional composition, or a cosmetic, paint, soap, bath oil or other desirably encapsulated product. The dosage form can be a solid, liquid, gel, suspension or any other form suitable for encapsulation.
[017] The term "encapsulated dosage form" refers to any dosage form encapsulated with a non-animal hydrocolloid film-forming composition as set forth herein.
The encapsulated dosage form can be in any form known to practitioners in the art, such as but not limited to a softgel or caplet.
The encapsulated dosage form can be in any form known to practitioners in the art, such as but not limited to a softgel or caplet.
[018] "Encapsulated" and other forms of the word "encapsulate" as used herein mean placing a dosage form inside of a film-forming composition, such that the dosage form is completely surrounded by the film-forming composition. By methods known to practitioners in the art, the dosage form can be inserted into the film-forming composition in some manner, or the film-forming composition can be wrapped around the dosage form.
[019] A "capsule shell" as used herein refers to the film-forming composition described herein when used to encapsulate a substance such as a drug dosage form.
[020] "Capsule" refers to a softgel, caplet, or any other encapsulated dosage form known to practitioners in the art, or a portion thereof.
[021] The phrase "solids content" as used herein refers to the ratio of the weight of the dry film-forming composition components to the total weight of the composition, expressed as a percentage.
[022] Manufacture of uniform capsule shells requires a film-forming composition that has good "machineability," i.e., it is important that the film-forming composition be able to be brought into contact with rollers or other machine parts during processing without sticking onto these machine parts. However, some stickiness is required for proper seam formation and, in the manufacture of caplets, to improve contact between the encapsulating material and the solid tablet core.
[023] Physical characteristics for proper machineability of the film-forming composition described herein during film formation, capsule shell formation and encapsulation of a dosage form, regardless of the method or machine used, include desirable extensibility, sealability, viscosity and tensile strength at rupture of the film-forming composition as known to practitioners in the art.
[024] The term "extensibility" as used herein defines the increase in length of the film-forming composition set forth herein once formed into a dry film having a moisture content of from about 5% to about 20%, on application of a tensile force (pull). A
desirable maximum increase in length at rupture for a 50 mm long film of about 20 mm wide is between about 20 mm and about 80 mm, most desirably between about 35 mm and about 70 mm.
desirable maximum increase in length at rupture for a 50 mm long film of about 20 mm wide is between about 20 mm and about 80 mm, most desirably between about 35 mm and about 70 mm.
[025] The term "sealability" refers to the ability of one or more film of the film-forming composition set forth herein to fuse together using methods known to practitioners in the art, such as but not limited to the application of heat and/or pressure. The seam that is created in the film upon fusing should be continuous and strong to prevent leakage of encapsulated dosage forms.
[026] The viscosity of the film-forming composition is desirably in the range of from about 100 cP to about 1200 cP, and more desirably in the range of from about 350 cP to about 750 cP, as measured at 90 C using a mechanical rheometer at a shear rate of 0 to 100 per second in two (2) minutes, a Brookfield viscometer, or other device known to practitioners in the art to measure viscosity.
[027] The tensile strength at rupture of a film made from the film-forming composition set forth herein having a moisture content of between about 5% and about 20%
is desirably between about 5 N and about 40 N, most desirably between about 10 N and about 25 N, as measured by methods known to practitioners in the art. One suitable means of measuring the tensile strength at rupture is by use of a TA-XT2 Texture Analyzer by Stable Micro Systems (Surrey, UK).
is desirably between about 5 N and about 40 N, most desirably between about 10 N and about 25 N, as measured by methods known to practitioners in the art. One suitable means of measuring the tensile strength at rupture is by use of a TA-XT2 Texture Analyzer by Stable Micro Systems (Surrey, UK).
[028] The film-forming composition comprises a blend of iota and kappa carrageenan, thus overcoming the recognized deficiencies of kappa carrageenan. A film-forming composition having the desired physical properties of extensibility, sealability, viscosity and tensile strength at rupture is provided. The kappa carrageenan provides gel strength while the iota carrageenan provides flexibility to the hydrocolloid film. No additional gelling salts or processing aids, such as surfactants or buffers, are necessary for producing a suitable film-forming composition of the invention. Thus, due to the use of less expensive starting materials and fewer ingredients, the film-forming composition set forth herein provides a more cost effective film-forming material than heretofore available.
[029] The film-forming composition comprises from about 1% to about 15% by weight commercially available iota carrageenan, such as but not limited to TIC
Pretested COLLOID
881M, available from TIC Gums of Belcamp, Maryland. Other available forms of iota carrageenan as known to practitioners in the art are also suitable for use herein. Desirably, iota carrageenan is present in an amount of from 2.3% to about 10% by weight of the composition, more desirably in an amount of from 2.5% to about 7.5% by weight of the composition.
Pretested COLLOID
881M, available from TIC Gums of Belcamp, Maryland. Other available forms of iota carrageenan as known to practitioners in the art are also suitable for use herein. Desirably, iota carrageenan is present in an amount of from 2.3% to about 10% by weight of the composition, more desirably in an amount of from 2.5% to about 7.5% by weight of the composition.
[030] The film-forming composition also comprises kappa carrageenan in an amount less than or equal to 50% by weight of total carrageenan in the film-forming composition.
Desirably, kappa carrageenan is present in an amount of less than or equal to about 100% by weight of iota carrageenan, more desirably in an amount less than about 100%
by weight of iota carrageenan, provided the total amount of carrageenan does not exceed 20% by weight of the composition. Kappa carrageenan is present in an amount of from about 0.1 % to about 15% by weight of the composition, and more desirably in an amount of from about 0.5%
to about 7.5%
by weight of the composition. Kappa carrageenan from any commercial source is acceptable, such as TIC Pretested COLLOID 710H, available from TIC Gums of Belcamp, Maryland.
Other commercial sources of kappa carrageenan as known to practitioners in the art are also suitable for use herein.
Desirably, kappa carrageenan is present in an amount of less than or equal to about 100% by weight of iota carrageenan, more desirably in an amount less than about 100%
by weight of iota carrageenan, provided the total amount of carrageenan does not exceed 20% by weight of the composition. Kappa carrageenan is present in an amount of from about 0.1 % to about 15% by weight of the composition, and more desirably in an amount of from about 0.5%
to about 7.5%
by weight of the composition. Kappa carrageenan from any commercial source is acceptable, such as TIC Pretested COLLOID 710H, available from TIC Gums of Belcamp, Maryland.
Other commercial sources of kappa carrageenan as known to practitioners in the art are also suitable for use herein.
[031] A mixture of kappa carrageenan and a glucomannan such as but not limited to konjac flour, as known to practitioners in the art, may be used in place of some or all of the kappa carrageenan in the composition. One example of such a mixture is NUTRICOL GP75 1, a commercially available blend of kappa carrageenan and konjac flour, sold by FMC Biopolymer of Philadelphia, PA. Other blends of kappa carrageenan and glucomannans as known to practitioners in the art are also suitable for use herein in place of some or all of the kappa carrageenan.
[032] The total amount of carrageenan in the composition is less than or equal to about 20% by weight of the composition. Desirably, the total amount of carrageenan is less than or equal to about 10% by weight of the composition.
[033] Other hydrocolloids as known to practitioners in the art optionally can be present in the composition in limited amounts. The total amount of all hydrocolloids, including the carrageenans but excluding bulking agents, desirably does not exceed 22% by weight of the composition. Desirably, such hydrocolloids include viscosity agents that can modify the physical properties of the final gel or film. Practitioners in the art appreciate that adding plant-based hydrocolloids and gums to a film-forming composition can increase the viscosity of the composition. Viscosity agents suitable for use in the composition disclosed herein include, but are not limited to alginates, guar, pectin, locust bean gum, xanthan gum, agar, unmodified starch, modified pregelatinized starch, gellan gum and other viscosity agents known to practitioners in the art. Hydrocolloids acting as viscosity agents are optionally added to the film-forming composition in amounts less than or equal to about 2% by weight of the composition to increase the viscosity of the composition.
[034] The hydrocolloids, including those used as viscosity agents but excluding those used as bulking agents and carrageenans, can be present in the composition in an amount less than 100% by weight of the amount of iota carrageenan, desirably in an amount less than or equal to the amount of kappa carrageenan, and most desirably in an amount less than 2% by weight of the composition. The total amount of all hydrocolloids, including the carrageenans but excluding bulking agents, desirably does not exceed 22% by weight of the composition.
[035] The film-forming composition comprises a bulking agent, such as a modified starch. The bulking agent increases the solids content of the film-forming composition, thereby contributing to a reduction in the amount of energy and time necessary to dry the film-forming composition once formed into a capsule or capsule shell. The bulking agent desirably is a low viscosity modified starch that contributes only minimally to gel formation, but serves to increase film strength and sealability of the film-forming composition, and reduces water content in the wet formulation. Further, the bulking agent provides some adhesiveness, minimizes syneresis of the kappa carrageenan, improves seam formation and increases viscosity of the film-forming composition. Desirably, the bulking agent is a low viscosity esterified starch as known to practitioners in the art, such as but not limited to N-LOK (starch sodium octenyl succinate), a modified waxy maize starch with corn syrup solids added, sold by National Starch & Chemical Company of Bridgewater, New Jersey. Desirably, the modified starch is corn or maize based.
Optionally, up to 30% of the modified starch can be replaced with conventional unmodified starch and/or modified pregelatinized starch such as, but not limited to, Ultra Sperse M by National Starch and Chemical Company of Bridgewater, New Jersey. The film-forming composition has a weight ratio of bulking agent to total carrageenan of from about 1:1 to about 20:1, and desirably from about 2:1 to about 15:1. The bulking agent comprises from about 10%
to about 60% by weight of the total film-forming composition and desirably from about 15% to about 50% by weight of the total film-forming composition. Those skilled in the art will recognize other bulking agents, such as but not limited to modified pregelatinized starch, guar gum, gum arabic and locust bean gum, can be used in the composition. However, hydrolyzed starches and dextrins are not recommended for use in the composition.
Optionally, up to 30% of the modified starch can be replaced with conventional unmodified starch and/or modified pregelatinized starch such as, but not limited to, Ultra Sperse M by National Starch and Chemical Company of Bridgewater, New Jersey. The film-forming composition has a weight ratio of bulking agent to total carrageenan of from about 1:1 to about 20:1, and desirably from about 2:1 to about 15:1. The bulking agent comprises from about 10%
to about 60% by weight of the total film-forming composition and desirably from about 15% to about 50% by weight of the total film-forming composition. Those skilled in the art will recognize other bulking agents, such as but not limited to modified pregelatinized starch, guar gum, gum arabic and locust bean gum, can be used in the composition. However, hydrolyzed starches and dextrins are not recommended for use in the composition.
[036] The film-forming composition further comprises one or more plasticizer selected from those known to practitioners in the art. A plasticizer provides extensibility and improved sealability in the film-forming composition, allowing for formation of strong seams during encapsulation of a dosage form. Also, plasticizers reduce the tensile strength of films made from the film-forming composition. A desirable plasticizer is a combination of sorbitol and maltitol, most desirably a combination of a non-crystallizing sorbitol, such as SORBITOL
SPECIALTM
acquired from SPI Polyols of New Castle, Delaware, and LYCASIN , a maltitol acquired from Roquette of Keokuk, Iowa. Non-crystallizing sorbitol is desirable over regular sorbitol because regular sorbitol is believed to cause blooming in capsules, a defect where white crystals form on the surface of capsules during storage. Acceptable substitutes for non-crystallizing sorbitol include other plasticizers as known to practitioners in the art, such as but not limited to glycerin, polyethylene glycol and combinations thereof. The amount of plasticizer used in the film-forming composition is from about 10% to about 50% by weight of the total film-forming composition, and desirably from about 12% to about 36% by weight of the total film-forming composition.
SPECIALTM
acquired from SPI Polyols of New Castle, Delaware, and LYCASIN , a maltitol acquired from Roquette of Keokuk, Iowa. Non-crystallizing sorbitol is desirable over regular sorbitol because regular sorbitol is believed to cause blooming in capsules, a defect where white crystals form on the surface of capsules during storage. Acceptable substitutes for non-crystallizing sorbitol include other plasticizers as known to practitioners in the art, such as but not limited to glycerin, polyethylene glycol and combinations thereof. The amount of plasticizer used in the film-forming composition is from about 10% to about 50% by weight of the total film-forming composition, and desirably from about 12% to about 36% by weight of the total film-forming composition.
[037] The film-forming composition comprises water in an amount sufficient to bring the total composition to 100% by weight. Generally, water is present in an amount from about 10% to about 90% by weight of the composition. Desirably, water is present in an amount of from about 14% to about 79% by weight of the composition, and more desirably from about 20%
to about 60% by weight of the composition. It is desirable that the water is distilled water. If the film-forming composition is used to form medicinal, nutritional or other softgels or caplets intended for human use or consumption, purified distilled water is desirable.
to about 60% by weight of the composition. It is desirable that the water is distilled water. If the film-forming composition is used to form medicinal, nutritional or other softgels or caplets intended for human use or consumption, purified distilled water is desirable.
[038] As known to practitioners in the art, the film-forming composition can also contain other ingredients, such as taste modifiers, opacifying and coloring agents, preservatives, and similar additives that do not significantly alter film-forming capabilities. The additives can be added in any amount known to practitioners in the art to achieve the desired effect without altering the film-forming properties of the composition. Desirably, the total amount of all additives does not exceed 5% by weight of the composition, more desirably, it does not exceed 2% by weight of the composition.
[039] The solids content of the wet film-forming composition is from about 11%
to about 90% by weight of the wet composition, desirably from about 40% to about 90% by weight, most desirably from about 50% to about 80% by weight of the wet composition.
to about 90% by weight of the wet composition, desirably from about 40% to about 90% by weight, most desirably from about 50% to about 80% by weight of the wet composition.
[040] The desired physical characteristics of the wet film-forming composition are based upon the encapsulation of dosage forms using encapsulation machinery as known to practitioners in the art. One method of capsule production known in the art uses a rotary die process in which a molten mass of a gelatin film-forming composition is fed from a reservoir onto cooled drums to form two spaced sheets or ribbons in a semi-molten state.
These sheets are fed around rollers and brought together at a convergent angle into the nip of a pair of roller dies that include opposed die cavities. A dosage form is fed into the wedge-shaped joinder of the sheets. The sheets are continuously conveyed between the dies, with the dosage form to be encapsulated, such as a medicament, being trapped between the sheets inside the die cavities.
The sheets are then pressed together ("sealed"), and severed around each die so that opposed edges of the sheets seal together to encapsulate or enrobe the dosage form, forming a capsule.
The part of the sheet that is severed from the segments forming the capsules is collected and either discarded or recycled, depending on the content of the dosage form. The capsules are dried to increase the film integrity and packaged for later distribution and sale. Other encapsulating machines and methods applicable for use with the film-forming composition described herein are known to practitioners in the art, such as but not limited to the method of enrobing hard tablets (SOFLETTM) as disclosed and claimed in U.S. Patent Nos.
5,146,730 and 5,549,983.
These sheets are fed around rollers and brought together at a convergent angle into the nip of a pair of roller dies that include opposed die cavities. A dosage form is fed into the wedge-shaped joinder of the sheets. The sheets are continuously conveyed between the dies, with the dosage form to be encapsulated, such as a medicament, being trapped between the sheets inside the die cavities.
The sheets are then pressed together ("sealed"), and severed around each die so that opposed edges of the sheets seal together to encapsulate or enrobe the dosage form, forming a capsule.
The part of the sheet that is severed from the segments forming the capsules is collected and either discarded or recycled, depending on the content of the dosage form. The capsules are dried to increase the film integrity and packaged for later distribution and sale. Other encapsulating machines and methods applicable for use with the film-forming composition described herein are known to practitioners in the art, such as but not limited to the method of enrobing hard tablets (SOFLETTM) as disclosed and claimed in U.S. Patent Nos.
5,146,730 and 5,549,983.
[041] To form a capsule using the film forming composition described herein, the film-forming composition is first formed by mixing all materials together and heating with stirring until a smooth liquid, free of particulates, is formed. Desirably, the hydrocolloids comprising kappa and iota carrageenan are mixed together with a bulking agent and any other dry optional ingredients. A plasticizer is added with mixing to the dry mix. Water is then added with continued mixing and the entire mixture is heated until the ingredients are uniformly dispersed.
Additives such as colorants, opacifiers, preservatives, flavorants and the like as known to practitioners in the art can be added as desired during the mixing process.
Additives such as colorants, opacifiers, preservatives, flavorants and the like as known to practitioners in the art can be added as desired during the mixing process.
[042] In one embodiment, all the dry ingredients (kappa carrageenan, iota carrageenan, and bulking agent, as well as dry additives) are blended together to form a dry mix. In a separate container, water and plasticizer, as well as any liquid additives, are mixed together as a liquid mix and heated to at least about 75 C, desirably about 90 C. While stirring the hot liquid mix, the dry mix is slowly added to the hot liquid mix to minimize formation of large lumps. The dispersion formed is heated with mixing to a temperature of from about 85 C to about 95 C. The temperature is maintained with mixing until the film-forming composition melts to form a smooth liquid free of particulates.
[043] The film-forming composition in liquid form can be subjected to one or more treatments as known to practitioners in the art. The treatments can include casting the liquefied composition into a ribbon or sheet, drying the ribbon, and conditioning it to a predetermined moisture content, typically from about 5% to about 20% moisture by weight of the ribbon, preferably from about 5% to about 15% moisture by weight of the ribbon, as known to practitioners in the art. The dry ribbon or sheet can be stored, or used directly after drying.
Desirably, the dry ribbon or sheet is used to encapsulate a dosage form, such as by use of a rotary die encapsulation machine, although other methods of encapsulation as known to practitioners in the art may also be used. Alternatively, the film-forming composition can be cast into a wet film on the drum of a rotary die encapsulation machine and the wet film used to encapsulate a dosage form. Encapsulated dosage forms include, but are not limited to drug dosage forms, nutritional supplements, cosmetics, bath oils and gels, paint balls and the like.
Desirably, the dry ribbon or sheet is used to encapsulate a dosage form, such as by use of a rotary die encapsulation machine, although other methods of encapsulation as known to practitioners in the art may also be used. Alternatively, the film-forming composition can be cast into a wet film on the drum of a rotary die encapsulation machine and the wet film used to encapsulate a dosage form. Encapsulated dosage forms include, but are not limited to drug dosage forms, nutritional supplements, cosmetics, bath oils and gels, paint balls and the like.
[044] The film-forming composition can also be formed by adding a dry mix and a liquid mix as defined elsewhere herein to an extruder, wherein the dry and liquid mixes are mixed together and heated, then extruded through dies into sheets, films or tubes. A premixed film-forming composition may also be added to an extruder for extrusion to form sheets, films or tubes. The extruded composition is fed to an encapsulation machine for the manufacture of encapsulated dosage forms. Encapsulated dosage forms include, but are not limited to drug dosage forms, nutritional supplements, cosmetics, bath oils and gels, paint balls and the like.
[045] As used herein, the term "sheet" or "ribbon" is meant to include any form of the film-forming composition suitable for encapsulation of a dosage form as known to practitioners in the art, including but not limited to sheets, films, tubes, hemispheres, cones and the like. Wet cast or extruded ribbons are desirably from 0.4 mm to about 1.0 mm thick, though other thicknesses can be formed and used as known to practitioners in the art. Dry ribbons are typically from about 0.5 mm to about 0.7 mm thick, though thicker or thinner dry ribbons can be formed as known to practitioners in the art. The thickness of a dry or wet ribbon is determinable by a practitioner in the art based on the desired end use. Desirably, the moisture content of the dry ribbon is from about 5% to about 20% by weight of the ribbon, more desirably from about 5% to about 15% by weight of the ribbon.
[046] Once the film-forming composition is formed into the desired shape, it can be used to encapsulate dosage forms including liquids, solids, gels and suspensions, according to methods known to practitioners in the art. Typically, for encapsulation, the film-forming composition is heated to and maintained at a temperature of from about 60 C to about 100 C, desirably from about 75 C to about 95 C, during the encapsulation process. For example, when a rotary die encapsulation machine is used, the film-forming composition is heated by a wedge that is located above the dies. The film-forming composition is maintained at a temperature of from about 60 C to about 99 C, typically from about 75 C to about 95 C, during encapsulation of the dosage form. Other examples of equipment, heating methods and temperatures therefore are known to practitioners in the art.
[047] During encapsulation, the ribbon is frequently lubricated to prevent adherence to the machinery and prevent entrapment of air bubbles within the capsule.
Suitable lubricants are known to practitioners in the art, and include, but are not limited to, triglycerides, mineral oil and acetylated monoglycerides.
Suitable lubricants are known to practitioners in the art, and include, but are not limited to, triglycerides, mineral oil and acetylated monoglycerides.
[048] Once formed, the capsule shell of dry film-forming composition desirably has a solids content of from about 80% to about 95% by weight of the dry composition. Iota carrageenan is present in an amount of from about 2% to about 20% by weight of the dry composition, and desirably from about 2.5% to about 10% by weight of the dry composition.
Kappa carrageenan is present in an amount of from about 0.4% to about 20% by weight of the dry composition, and desirably from about 0.5% to about 10% by weight of the dry composition.
The bulking agent is present in an amount of from about 10% to about 80% by weight of the dry composition, and desirably from about 40% to about 70% by weight of the dry composition. The plasticizer is present in an amount of from about 15% to about 40% by weight of the dry composition, and desirably from about 20% to about 30% by weight of the dry composition. The water content is from about 2% to about 10% by weight of the dry composition, and desirably from about 5% to about 7% by weight of the dry composition.
Examples
Kappa carrageenan is present in an amount of from about 0.4% to about 20% by weight of the dry composition, and desirably from about 0.5% to about 10% by weight of the dry composition.
The bulking agent is present in an amount of from about 10% to about 80% by weight of the dry composition, and desirably from about 40% to about 70% by weight of the dry composition. The plasticizer is present in an amount of from about 15% to about 40% by weight of the dry composition, and desirably from about 20% to about 30% by weight of the dry composition. The water content is from about 2% to about 10% by weight of the dry composition, and desirably from about 5% to about 7% by weight of the dry composition.
Examples
[049] Examples of film-forming compositions of the invention are set forth below.
Composition components are set forth by weight percentage of the total weight of the composition; "t" refers to iota carrageenan and "K" refers to kappa carrageenan.
Composition components are set forth by weight percentage of the total weight of the composition; "t" refers to iota carrageenan and "K" refers to kappa carrageenan.
[050] Kappa and iota carrageenan are standardized carrageenan (standardized with maltodextrin) supplied by TIC Gums of Belcamp, Maryland. Standardized kappa carrageenan is supplied as TIC PRETESTED COLLOID 710H. Standardized iota carrageenan is supplied as TIC PRETESTED COLLOID 881M. The modified starch is N-LOK , starch sodium octenyl succinate with corn syrup solids added, and the modified pregelatinized starch is Ultra Sperse M, both supplied by National Starch and Chemical Company of Bridgewater, New Jersey.
SORBITOL SPECIALTM is non-crystallizing sorbitol supplied by SPI Polyols of New Castle, Delaware. The maltitol used is LYCASIN , supplied by Roquette of Keokuk, Iowa.
Glycerin is USP GLYCERIN acquired from commercial sources such as Henkel of Cincinnati, Ohio.
Titanium dioxide is supplied by Warner-Jenkinson Co., Inc., of South Plainfield, New Jersey.
Water is purified, distilled water prepared inhouse.
Kappa Carrageenan 2.0%
Iota Carrageenan 2.0%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Sorbitol SpecialTM 36.0%
Distilled Water 40.0%
Kappa Carrageenan 2.0%
Iota Carrageenan 2.0%
Modified Starch 15.0%
Ratio of starch:total carrageenan 7.5:2 Sorbitol SpecialTM 35.0%
Titanium Dioxide 0.5%
Distilled Water 45.5%
Kappa Carrageenan 1.0%
Iota Carrageenan 3.0%
Modified Starch 20%
Ratio of starch:total carrageenan 5:1 Sorbitol SpecialTM 30.0%
Titanium Dioxide 1.0%
Distilled Water 45.0%
Kappa Carrageenan 2.0%
Iota Carrageenan 3.0%
Modified Starch 20%
Ratio of starch:total carrageenan 4:1 Sorbitol SpecialTM 35.0%
Titanium Dioxide 0.5%
Distilled Water 39.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Glycerin (USP) 25.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Maltitol 25.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Glycerin (USP) 12.5%
Sorbitol SpecialTM 12.5%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 6.25:1 Maltitol 5.0%
Sorbitol S ecialTM 15.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 2.5%
Iota Carrageenan 2.5%
Modified Starch 23.0%
Ratio of starch:total carrageenan 4.6:1 Maltitol 16%
Sorbitol SpecialTM 8%
Titanium Dioxide -Distilled Water 48%
Kappa Carrageenan 1.5%
Iota Carrageenan 3.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 5:1 Maltitol 7.0%
Sorbitol SpecialTM 13.0%
Titanium Dioxide 0.10%
Distilled Water 49.90%
Kappa Carrageenan 1.5%
Iota Carrageenan 3.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 5:1 Maltitol 8.0%
Sorbitol SpecialTM 15.0%
Titanium Dioxide 0.10%
Distilled Water 46.90%
Kappa Carrageenan 2.5%
Iota Carrageenan 2.5%
Modified Starch 40.0%
Pregelatinized Starch 5.0%
Ratio of starch:total carrageenan 9:1 Maltitol 3.75%
Sorbitol SpecialTM 18.75%
Titanium Dioxide -Distilled Water 27.50%
SORBITOL SPECIALTM is non-crystallizing sorbitol supplied by SPI Polyols of New Castle, Delaware. The maltitol used is LYCASIN , supplied by Roquette of Keokuk, Iowa.
Glycerin is USP GLYCERIN acquired from commercial sources such as Henkel of Cincinnati, Ohio.
Titanium dioxide is supplied by Warner-Jenkinson Co., Inc., of South Plainfield, New Jersey.
Water is purified, distilled water prepared inhouse.
Kappa Carrageenan 2.0%
Iota Carrageenan 2.0%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Sorbitol SpecialTM 36.0%
Distilled Water 40.0%
Kappa Carrageenan 2.0%
Iota Carrageenan 2.0%
Modified Starch 15.0%
Ratio of starch:total carrageenan 7.5:2 Sorbitol SpecialTM 35.0%
Titanium Dioxide 0.5%
Distilled Water 45.5%
Kappa Carrageenan 1.0%
Iota Carrageenan 3.0%
Modified Starch 20%
Ratio of starch:total carrageenan 5:1 Sorbitol SpecialTM 30.0%
Titanium Dioxide 1.0%
Distilled Water 45.0%
Kappa Carrageenan 2.0%
Iota Carrageenan 3.0%
Modified Starch 20%
Ratio of starch:total carrageenan 4:1 Sorbitol SpecialTM 35.0%
Titanium Dioxide 0.5%
Distilled Water 39.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Glycerin (USP) 25.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Maltitol 25.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 20.0%
Ratio of starch:total carrageenan 5:1 Glycerin (USP) 12.5%
Sorbitol SpecialTM 12.5%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 1.5%
Iota Carrageenan 2.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 6.25:1 Maltitol 5.0%
Sorbitol S ecialTM 15.0%
Titanium Dioxide 0.5%
Distilled Water 50.5%
Kappa Carrageenan 2.5%
Iota Carrageenan 2.5%
Modified Starch 23.0%
Ratio of starch:total carrageenan 4.6:1 Maltitol 16%
Sorbitol SpecialTM 8%
Titanium Dioxide -Distilled Water 48%
Kappa Carrageenan 1.5%
Iota Carrageenan 3.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 5:1 Maltitol 7.0%
Sorbitol SpecialTM 13.0%
Titanium Dioxide 0.10%
Distilled Water 49.90%
Kappa Carrageenan 1.5%
Iota Carrageenan 3.5%
Modified Starch 25.0%
Ratio of starch:total carrageenan 5:1 Maltitol 8.0%
Sorbitol SpecialTM 15.0%
Titanium Dioxide 0.10%
Distilled Water 46.90%
Kappa Carrageenan 2.5%
Iota Carrageenan 2.5%
Modified Starch 40.0%
Pregelatinized Starch 5.0%
Ratio of starch:total carrageenan 9:1 Maltitol 3.75%
Sorbitol SpecialTM 18.75%
Titanium Dioxide -Distilled Water 27.50%
[051] The film-forming compositions of examples 1-12 were cast into films and dried to between about 5% and about 15% moisture. The films were cut into strips 20 mm wide by 50 mm long. The films for Examples 2-12 were tested for tensile strength at rupture and extensibility using a TA-XT2 Texture Analyzer manufactured by Stable Micro Systems, (Surrey, UK). The following table charts the tensile strength and extensibility of the resulting films, where the values are mean values with standard deviations taken from four (4) replicates.
Example # Tensile Strength at Rupture Maximum Extension at Rupture (mm) 2 10.7f0.2 53.1t3.3 3 14.8f0.7 63.6 4.7 4 12.9 0.5 45.7 2.1 5.8 ~ 0.4 43.2 1.6 6 13.2 t 1.2 51.4 2.2 7 7.1 f 0.6 45.9 8.3 8 15.6 2.4 64.9 5.7 9 10.3~0.3 42.4 2.2 29.7 2.0 56.6 2.0 11 18.7 f 4.5 41.4 9.2 12 29.5 0.6 59.8 7.2
Example # Tensile Strength at Rupture Maximum Extension at Rupture (mm) 2 10.7f0.2 53.1t3.3 3 14.8f0.7 63.6 4.7 4 12.9 0.5 45.7 2.1 5.8 ~ 0.4 43.2 1.6 6 13.2 t 1.2 51.4 2.2 7 7.1 f 0.6 45.9 8.3 8 15.6 2.4 64.9 5.7 9 10.3~0.3 42.4 2.2 29.7 2.0 56.6 2.0 11 18.7 f 4.5 41.4 9.2 12 29.5 0.6 59.8 7.2
[052] To demonstrate the desirable characteristics for kappa carrageenan, iota carrageenan and bulking agents used in this invention, commercially available kappa 5 carrageenan, iota carrageenan and a modified starch were formed into solutions and their viscosity, gel point, melting point and gel strength were measured. The materials used were as follows:
Kappa Carrageenan: Colloid 710H (Lot # 1025) from TIC Gums of Belcamp MD.
Iota Carrageenan: Colloid 881M (Lot # 1539) from TIC Gums of Belcamp MD.
10 Modified Starch (starch sodium octenyl succinate): N-Lok (Lot # FK17502) from National Starch & Chemical Co. of Bridgewater, New Jersey.
Procedure:
Kappa Carrageenan: Colloid 710H (Lot # 1025) from TIC Gums of Belcamp MD.
Iota Carrageenan: Colloid 881M (Lot # 1539) from TIC Gums of Belcamp MD.
10 Modified Starch (starch sodium octenyl succinate): N-Lok (Lot # FK17502) from National Starch & Chemical Co. of Bridgewater, New Jersey.
Procedure:
[053] A 3% dispersion of carrageenan in purified distilled water was prepared by heating the water to 70 C and adding the carrageenan with stirring. The dispersion was heated at 70 C until it became smooth and free of any particulates (non-dispersed carrageenan). Similarly, a 10% dispersion of modified starch in water was prepared.
[054] The viscosity, gelling, holding, frequency and heating (melting) profiles were measured using a mechanical rheometer (AR1000 Advanced Mechanical Rheometer manufactured by TA Instruments of New Castle, Delaware) using a 4 steel cone.
Viscosity was measured by shearing the sample at a rate of 0 to 120 per second in two (2) minutes.
Viscosity was measured by shearing the sample at a rate of 0 to 120 per second in two (2) minutes.
[055] The gelling profile was determined by dropping the temperature from 80 C
to C at 5 C per minute, with constant strain and frequency of 2% and 1Hz, respectively. The gelling point was determined to be the temperature at which the storage and loss moduli, G' and G" respectively, crossed. Following gelling, the sample was held at 10 C for 5 min to obtain a 5 holding profile. After the holding step, the mechanical spectrum (frequency profile) of the gel formed was determined by performing a frequency sweep from 0.1 Hz to 100Hz at 10 C, with constant strain of 2%. The storage modulus (G) at a frequency of 1 Hz was chosen as the gel strength of the gel formed by the carrageenan dispersion. The gel was then heated at a rate of 5 C per minute from 10 C to 95 C to obtain the melting profile of the gel, with constant strain 10 and frequency of 2% and 1 Hz, respectively. The melting point was determined to be the temperature at which the storage and loss moduli, G' and G" respectively, crossed. The results are set forth in Table 2.
Sample Viscosity Gelling point Melting point Gel Strength cP C C (Pa) 3% kappa carrageenan dispersion in water 618.4 40.6 60.3 35,740 3% iota carrageenan dis ersion in water 93.8 61.2 64.9 976 1.5% kappa carrageenan +
1.5% iota carrageenan 206.6 47.2 70.8 19,800 dispersion in water 10% starch sodium octenyl succinate 3.8 - - -
to C at 5 C per minute, with constant strain and frequency of 2% and 1Hz, respectively. The gelling point was determined to be the temperature at which the storage and loss moduli, G' and G" respectively, crossed. Following gelling, the sample was held at 10 C for 5 min to obtain a 5 holding profile. After the holding step, the mechanical spectrum (frequency profile) of the gel formed was determined by performing a frequency sweep from 0.1 Hz to 100Hz at 10 C, with constant strain of 2%. The storage modulus (G) at a frequency of 1 Hz was chosen as the gel strength of the gel formed by the carrageenan dispersion. The gel was then heated at a rate of 5 C per minute from 10 C to 95 C to obtain the melting profile of the gel, with constant strain 10 and frequency of 2% and 1 Hz, respectively. The melting point was determined to be the temperature at which the storage and loss moduli, G' and G" respectively, crossed. The results are set forth in Table 2.
Sample Viscosity Gelling point Melting point Gel Strength cP C C (Pa) 3% kappa carrageenan dispersion in water 618.4 40.6 60.3 35,740 3% iota carrageenan dis ersion in water 93.8 61.2 64.9 976 1.5% kappa carrageenan +
1.5% iota carrageenan 206.6 47.2 70.8 19,800 dispersion in water 10% starch sodium octenyl succinate 3.8 - - -
[056] The above results are within the desirable ranges for viscosity, gel point, melting point and gel strength for iota carrageenan, kappa carrageenan and a bulking agent. Desirably, the range for these parameters for dispersions of iota carrageenan, kappa carrageenan and a bulking agent as described above are as set forth below in Table 3.
Sample Viscosity Gelling point Melting point Gel Strength cP C C (Pa) 3% kappa carrageenan dis ersion in water 580 - 650 38 - 43 57 - 64 33,000 - 38,000 3% iota carrageenan dispersion in water 85 - 100 58 - 65 60 - 69 920 - 1,100 1.5% kappa carrageenan +
1.5% iota carrageenan 190 - 220 44 - 50 67 - 75 18,000 - 21,000 dispersion in water 10% starch sodium octenyl succinate 3-5 - - -
Sample Viscosity Gelling point Melting point Gel Strength cP C C (Pa) 3% kappa carrageenan dis ersion in water 580 - 650 38 - 43 57 - 64 33,000 - 38,000 3% iota carrageenan dispersion in water 85 - 100 58 - 65 60 - 69 920 - 1,100 1.5% kappa carrageenan +
1.5% iota carrageenan 190 - 220 44 - 50 67 - 75 18,000 - 21,000 dispersion in water 10% starch sodium octenyl succinate 3-5 - - -
[057] Although specific embodiments of the present invention have been described in detail, it is to be expressly understood that the invention is not limited thereto. The above detailed description of embodiments of the invention is provided for example only and should not be construed as limiting the invention. Modifications and substitutions will be apparent to those skilled in the art, and all modifications and substitutions that do not depart from the spirit of the invention are intended to be included within the scope of the appended claims.
Claims (8)
1. A method for preparing a film-forming composition, comprising:
a) mixing iota carrageenan in an amount of from about 1% to about 15% by weight of the composition, kappa carrageenan in an amount less than 100% by weight of the iota carrageenan and a bulking agent in a ratio of bulking agent to total carrageenan of from about 1:1 to about 20:1 to form a dry mixture;
b) mixing a plasticizer and water to form a liquid mixture;
c) heating the liquid mixture to a temperature of from about 75°C to about 90°C;
d) adding the dry mixture to the heated mixture with stirring to form a dispersion; and e) heating the dispersion with stirring to a temperature of from about 85°C to about 95°C to form a uniform dispersion.
a) mixing iota carrageenan in an amount of from about 1% to about 15% by weight of the composition, kappa carrageenan in an amount less than 100% by weight of the iota carrageenan and a bulking agent in a ratio of bulking agent to total carrageenan of from about 1:1 to about 20:1 to form a dry mixture;
b) mixing a plasticizer and water to form a liquid mixture;
c) heating the liquid mixture to a temperature of from about 75°C to about 90°C;
d) adding the dry mixture to the heated mixture with stirring to form a dispersion; and e) heating the dispersion with stirring to a temperature of from about 85°C to about 95°C to form a uniform dispersion.
2. The method of claim 1, further comprising casting a ribbon with the uniform dispersion.
3. The method of claim 2, further comprising feeding the ribbon into a rotary die encapsulation machine.
4. The method of claim 2, further comprising drying the ribbon to a moisture content of from abut 5% to about 20%.
5. The method of claim 4, further comprising feeding the dried ribbon into a rotary die encapsulation machine.
6. The method of claim 1, further comprising extruding the uniform dispersion.
7. The method of claim 6, wherein the extruded uniform dispersion is in the shape of a film, ribbon, sheet or tube.
8. The method of claim 7, further comprising feeding the extruded uniform dispersion into a rotary die encapsulation machine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/051,201 US6949256B2 (en) | 2002-01-18 | 2002-01-18 | Non-gelatin capsule shell formulation |
| US10/051,201 | 2002-01-18 | ||
| PCT/US2003/001134 WO2003061633A1 (en) | 2002-01-18 | 2003-01-15 | Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2473312A1 CA2473312A1 (en) | 2003-07-31 |
| CA2473312C true CA2473312C (en) | 2010-02-23 |
Family
ID=21969929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2473312A Expired - Fee Related CA2473312C (en) | 2002-01-18 | 2003-01-15 | Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6949256B2 (en) |
| EP (1) | EP1474115B1 (en) |
| JP (1) | JP2005529066A (en) |
| CN (1) | CN100467065C (en) |
| AT (1) | ATE459344T1 (en) |
| AU (1) | AU2003237365B2 (en) |
| CA (1) | CA2473312C (en) |
| DE (1) | DE60331524D1 (en) |
| MX (1) | MXPA04006914A (en) |
| WO (1) | WO2003061633A1 (en) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50015770D1 (en) * | 2000-12-29 | 2009-12-03 | Swiss Caps Rechte & Lizenzen | Method and device for producing moldings from a biopolymer material |
| US7887838B2 (en) * | 2002-01-18 | 2011-02-15 | Banner Pharmacaps, Inc. | Non-gelatin film and method and apparatus for producing same |
| ES2195774B1 (en) * | 2002-03-11 | 2004-11-01 | Premium Ingredients, S.L. | FOOD ADDITIVE. |
| US7713551B2 (en) * | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
| JP4414670B2 (en) * | 2003-04-10 | 2010-02-10 | 松谷化学工業株式会社 | Process for producing glucose polymer having ion exchange ability and composition containing the same |
| US20050048185A1 (en) * | 2003-04-14 | 2005-03-03 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible low viscosity polymannan gum films |
| JP2006526057A (en) * | 2003-04-14 | 2006-11-16 | エフ エム シー コーポレーション | Uniform and thermoreversible low viscosity polymannan gum film and soft capsule made therefrom |
| US20050013847A1 (en) * | 2003-04-14 | 2005-01-20 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible alginate films |
| US20050019295A1 (en) * | 2003-04-14 | 2005-01-27 | Fmc Corporation | Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| US20050008677A1 (en) * | 2003-04-14 | 2005-01-13 | Fmc Corporation | Delivery system of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
| US7816341B2 (en) * | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| US20050019294A1 (en) * | 2003-04-14 | 2005-01-27 | Fmc Corporation | Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| EP1706700A2 (en) * | 2003-11-12 | 2006-10-04 | National Paintball Supply, Inc. | Projectile, projectile core, and method of making |
| US20060088590A1 (en) * | 2004-10-22 | 2006-04-27 | Banner Pharmacaps, Inc. | Non-blooming gelatin and non-gelatin formulations |
| EA200701246A1 (en) * | 2004-12-09 | 2008-06-30 | Инсис Терапьютикс, Инк. | STABLE UNDER ROOM TEMPERATURE COMPOSITIONS OF DRONABINOL |
| US7905181B2 (en) * | 2005-02-05 | 2011-03-15 | Ciesiun Paul M | Bioluminescent paintball |
| US8479656B2 (en) * | 2005-02-05 | 2013-07-09 | Hydro-Caps, Llc | Water based paintball and method for fabricating water based paintballs |
| CN1276779C (en) * | 2005-07-01 | 2006-09-27 | 唐连德 | Hollow capsule material composition of plant polysaccharide and production of hollow capsule |
| US7861728B2 (en) * | 2006-02-10 | 2011-01-04 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition having an outer and inner pouch |
| US8920918B2 (en) * | 2005-10-31 | 2014-12-30 | Kee Action Sports Technology Holdings, Llc | Oil and polyethylene glycol fill material for use in paintball shells |
| PL1830667T3 (en) * | 2005-12-02 | 2010-06-30 | Cargill Inc | Low calorie fat substitute |
| EP3332788A1 (en) | 2006-02-03 | 2018-06-13 | Opko Renal, LLC | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| US7810507B2 (en) | 2006-02-10 | 2010-10-12 | R. J. Reynolds Tobacco Company | Smokeless tobacco composition |
| ES2670029T3 (en) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Therapy using vitamin D replenishment agent and vitamin D hormone replacement agent |
| CN100411614C (en) * | 2006-06-29 | 2008-08-20 | 郑建璋 | Production of tremella-polysaccharose capsules |
| CA2659775A1 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| JP5021263B2 (en) * | 2006-10-02 | 2012-09-05 | 中日本カプセル 株式会社 | Film composition |
| US8574624B2 (en) * | 2006-11-17 | 2013-11-05 | Corn Products Development, Inc. | Highly inhibited starch fillers for films and capsules |
| CA2683514C (en) | 2007-04-25 | 2019-07-09 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| KR101691876B1 (en) | 2007-04-25 | 2017-01-02 | 사이토크로마 인코포레이티드 | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
| US20090004231A1 (en) | 2007-06-30 | 2009-01-01 | Popp Shane M | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring |
| EP2377413B1 (en) | 2007-07-23 | 2017-03-01 | R.J. Reynolds Tobacco Company | Smokeless tobacco compositions and methods for treating tobacco for use therein |
| US20090181080A1 (en) * | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
| EP2234711B1 (en) * | 2008-01-25 | 2017-11-01 | RJ Reynolds Tobacco Company | Process for manufacturing breakable capsules useful in tobacco products |
| JP5539621B2 (en) * | 2008-01-28 | 2014-07-02 | 三生医薬株式会社 | Capsule skin composition and capsule |
| WO2009100306A1 (en) * | 2008-02-08 | 2009-08-13 | Method Products, Inc. | Consumer product packets with enhanced performance |
| EP3112476B1 (en) | 2008-04-02 | 2023-08-02 | EirGen Pharma Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| US8097047B2 (en) * | 2008-04-02 | 2012-01-17 | The Procter & Gamble Company | Fabric color rejuvenation composition |
| EP2108677A1 (en) * | 2008-04-10 | 2009-10-14 | Swiss Caps Rechte und Lizenzen AG | Thermoplastic starch-containing materials |
| US20100092548A1 (en) * | 2008-08-28 | 2010-04-15 | Viva Pharmaceuticals Inc. | Chewable softgel capsules |
| US20100064927A1 (en) * | 2008-09-17 | 2010-03-18 | Aldo Perrone | Starch-based paintball fill material |
| JP4875769B2 (en) * | 2008-09-26 | 2012-02-15 | 株式会社三協 | Soft capsule manufacturing method and manufacturing apparatus thereof |
| CH700543A2 (en) | 2009-03-03 | 2010-09-15 | Innogel Ag | Film based on starch. |
| SI2432455T1 (en) | 2009-05-18 | 2015-04-30 | Sigmoid Pharma Limited | Composition comprising oil drops |
| BRPI1016013A2 (en) * | 2009-06-29 | 2016-04-26 | Mcneil Ppc Inc | pharmaceutical tablet containing a capsule filled with liquid. |
| EP2464341B1 (en) | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| US8464726B2 (en) | 2009-08-24 | 2013-06-18 | R.J. Reynolds Tobacco Company | Segmented smoking article with insulation mat |
| CN102625715B (en) | 2009-09-10 | 2014-06-11 | Fmc有限公司 | Seamless alginate capsules |
| FR2954162B1 (en) * | 2009-12-23 | 2012-03-09 | Oreal | COSMETIC COMPOSITION COMPRISING AT LEAST TWO GUMES OF CARRAGHENANES |
| US20110171281A1 (en) * | 2010-01-14 | 2011-07-14 | Karl Wei Cao | Soft capsule composition and method of use |
| US8101203B2 (en) * | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| US8101204B2 (en) * | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| HUE048464T2 (en) | 2010-03-29 | 2020-07-28 | Opko Ireland Global Holdings Ltd | Methods and compositions for reducing parathyroid levels |
| US10028520B2 (en) | 2010-09-02 | 2018-07-24 | R.J. Reynolds Tobacco Company | Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method |
| JP5923029B2 (en) * | 2010-11-22 | 2016-05-24 | 富士カプセル株式会社 | Soft capsule film |
| JP5149465B2 (en) * | 2010-11-22 | 2013-02-20 | 富士カプセル株式会社 | Soft capsule film |
| KR101401193B1 (en) * | 2010-11-22 | 2014-05-28 | 후지 캡슐 가부시키가이샤 | Soft capsule coating |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CN102100681B (en) * | 2011-01-28 | 2012-07-25 | 广东仙乐制药有限公司 | Vegetal shell of soft capsule |
| CN102342509B (en) * | 2011-09-15 | 2013-04-24 | 山东商业职业技术学院 | Konjak polysaccharide compound soft capsule shell and preparation method thereof |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| CN102772386B (en) * | 2012-07-30 | 2015-08-19 | 广西南宁汇润生物科技有限公司 | Plant capsule compound adhesive and preparation method thereof |
| KR101847947B1 (en) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | Stabilized modified release vitamin d formulation |
| CA2905367A1 (en) * | 2013-03-15 | 2014-09-25 | Banner Life Sciences Llc | Non-gelatin enteric soft capsules |
| CN104055748B (en) * | 2013-03-21 | 2018-12-25 | 中国科学院化学研究所 | It is used to prepare the composition of the hard capsule comprising converted starch matrix |
| FR3004070B1 (en) * | 2013-04-05 | 2015-07-31 | Bel Fromageries | PROCESS FOR COATING CHEESE PRODUCTS |
| JP5769760B2 (en) | 2013-06-25 | 2015-08-26 | アール．ピー． シェーラー テクノロジーズ エルエルシー | Shell forming composition for soft capsule and soft capsule |
| WO2015008399A1 (en) | 2013-07-18 | 2015-01-22 | 富士カプセル株式会社 | Soft capsule coating |
| CA2997734C (en) * | 2013-09-13 | 2022-01-04 | Phood Station | Encapsulated food products and methods of making same |
| GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US10772841B2 (en) | 2014-04-07 | 2020-09-15 | Patheon Softgels Inc. | Opioid abuse-deterrent controlled release formulations |
| US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
| EP3145500A1 (en) | 2014-05-23 | 2017-03-29 | Sigmoid Pharma Limited | Celecoxib formulations useful for treating colorectal cancer |
| SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
| WO2016047825A1 (en) * | 2014-09-25 | 2016-03-31 | 코스맥스바이오 주식회사 | Vegetable soft capsule composition not comprising chemical metal salts |
| CA2966801A1 (en) | 2014-11-07 | 2016-05-12 | Sigmoid Pharma Limited | Compositions comprising cyclosporin |
| US20160157515A1 (en) | 2014-12-05 | 2016-06-09 | R.J. Reynolds Tobacco Company | Smokeless tobacco pouch |
| JP5977470B1 (en) * | 2015-08-05 | 2016-08-24 | 富士カプセル株式会社 | Composition for soft capsule film |
| US9766114B2 (en) | 2015-08-26 | 2017-09-19 | R.J. Reynolds Tobacco Company | Capsule object inspection system and associated method |
| US10058125B2 (en) | 2015-10-13 | 2018-08-28 | Rai Strategic Holdings, Inc. | Method for assembling an aerosol delivery device |
| CN106605882A (en) * | 2015-10-27 | 2017-05-03 | 中国矿业大学(北京) | Fruit jelly with health function and preparation method thereof |
| US10314334B2 (en) | 2015-12-10 | 2019-06-11 | R.J. Reynolds Tobacco Company | Smoking article |
| US10285433B2 (en) | 2016-01-21 | 2019-05-14 | R.J. Reynolds Tobacco Company | Capsule object rupture testing system and associated method |
| TWI747893B (en) | 2016-03-28 | 2021-12-01 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | Methods of vitamin d treatment |
| US10329068B2 (en) | 2016-05-23 | 2019-06-25 | R.J. Reynolds Tobacco Company | Flavoring mechanism for a tobacco related material |
| US11058143B2 (en) | 2017-10-19 | 2021-07-13 | R.J. Reynolds Tobacco Company | Smoking-related article inspection systems and associated methods |
| CN107823176A (en) * | 2017-12-08 | 2018-03-23 | 江苏力凡胶囊有限公司 | A kind of natural plant gum softgel shell and preparation method thereof |
| CN112336698A (en) * | 2019-08-09 | 2021-02-09 | 南京科宁检测科技有限公司 | Rapidly disintegrating vaginal soft capsule composition and preparation method thereof |
| US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
| US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US11707074B2 (en) | 2020-04-09 | 2023-07-25 | Kim Schwarz | Edible hydration pod and method of manufacturing an edible hydration pod |
| WO2022197983A1 (en) * | 2021-03-17 | 2022-09-22 | Procaps Sa | Pre-filling system to eliminate bubbles inside capsules having a solid dosage form |
| CN113712935B (en) * | 2021-09-13 | 2023-11-17 | 陕西百瑞维力生物科技有限公司 | Modified vegetable gum soft capsule shell and preparation method thereof |
| GB2618381A (en) | 2022-05-06 | 2023-11-08 | Cosmetic Warriors Ltd | Composition |
| EP4335892A1 (en) | 2022-09-06 | 2024-03-13 | B'Zeos Switzerland SA | Seaweed and cellulose based film |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL275026A (en) | 1953-06-10 | |||
| US2802000A (en) | 1953-08-13 | 1957-08-06 | Nat Starch Products Inc | Ungelatinized cold water soluble starch ethers |
| US2825727A (en) | 1954-05-19 | 1958-03-04 | Nat Starch Products Inc | Ungelatinized starch products of improved properties and method of making the same |
| LU37997A1 (en) | 1959-12-01 | |||
| US3058827A (en) | 1960-02-09 | 1962-10-16 | Eastman Kodak Co | Dialdehyde starch as gelatin hardener |
| US3499962A (en) | 1967-08-24 | 1970-03-10 | Nat Starch Chem Corp | Encapsulation of water insoluble materials |
| US3607394A (en) | 1969-05-29 | 1971-09-21 | Felix Joseph Germino | Novel pregelatinized starches and process for preparing same |
| US3865603A (en) | 1972-07-17 | 1975-02-11 | Nat Starch Chem Corp | Modified starch-extended gelatin compositions |
| JPS50105766A (en) | 1974-01-29 | 1975-08-20 | ||
| JPS5717692B2 (en) | 1974-01-29 | 1982-04-12 | ||
| US4009291A (en) | 1974-03-25 | 1977-02-22 | General Foods Corporation | Cold water soluble stable bulked starch |
| US3956173A (en) | 1974-07-05 | 1976-05-11 | Hercules Incorporated | Preparation of gels based on carrageenan |
| CA1045936A (en) | 1975-03-24 | 1979-01-09 | Frederick W. Comer | Clear, elastic, water gels based on carrageenan |
| US4129134A (en) | 1975-04-14 | 1978-12-12 | Philip Morris Incorporated | Smoking article |
| US4026986A (en) | 1975-05-22 | 1977-05-31 | The Dow Chemical Company | Capsule shell |
| US4231803A (en) | 1978-05-22 | 1980-11-04 | Anheuser-Busch Incorporated | Starch adhesive composition containing an oxidized waxy starch ester |
| US4276320A (en) | 1980-01-25 | 1981-06-30 | Fmc Corporation | Compositions and method for preparing dessert gels |
| FR2508051B1 (en) | 1981-06-23 | 1986-12-05 | Roquette Freres | COMPOSITION AND METHOD FOR FORMING A TEMPORARY PROTECTIVE COATING AND OBJECT THUS PROTECTED |
| FR2540153B1 (en) | 1982-10-12 | 1987-02-13 | Roquette Freres | COMPOSITION AND METHOD FOR COATING PAPER AND CARDBOARD, PROCESS FOR PREPARING THE COMPOSITION AND PAPER AND CARDBOARD THUS OBTAINED |
| US4643894A (en) | 1984-07-24 | 1987-02-17 | Colorcon, Inc. | Maltodextrin coating |
| US4615897A (en) | 1985-02-25 | 1986-10-07 | Nabisco Brands, Inc. | Cold water soluble gelatin |
| FR2593510B1 (en) | 1985-07-31 | 1989-07-13 | Werner & Pfleiderer | PROCESS FOR THE PREPARATION OF HIGH VISCOSITY POLYHEXAMETHYLENEADIPAMIDE |
| DE3529694A1 (en) | 1985-08-20 | 1987-02-26 | Scherer Gmbh R P | GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION |
| US4795642A (en) | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
| JPS63118229A (en) | 1986-11-07 | 1988-05-23 | Idemitsu Petrochem Co Ltd | Preparation of thermoplastic resin sheets |
| GB8628068D0 (en) | 1986-11-24 | 1986-12-31 | Unilever Plc | Aqueous gel comprising carrageenan |
| CN1036967A (en) | 1988-02-04 | 1989-11-08 | 武田药品工业株式会社 | Edible film |
| US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| US5089307A (en) | 1989-05-23 | 1992-02-18 | Mitsubishi Rayon Co., Ltd. | Edible film and method of making same |
| FI102479B1 (en) | 1989-07-11 | 1998-12-15 | Warner Lambert Co | Polymer-based blend compositions containing modified starch for its structure |
| PT94658B (en) | 1989-07-18 | 1997-02-28 | Warner Lambert Co | PROCESS FOR THE PREPARATION OF POLYMERIC BASED COMPOSITIONS OF DESERATED FRUIT AND PRODUCTS THAT CONTAIN THEM |
| KR0178391B1 (en) | 1989-07-18 | 1999-05-15 | 토마스 디. 몰리터노 | Polymer base blend compositions containing destructured starch |
| CN1048861A (en) | 1989-07-20 | 1991-01-30 | 沃纳-兰伯特公司 | What contain disordered structure starch is the blend compositions of base-material with the polymkeric substance |
| US5146730A (en) | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
| JPH03121825A (en) | 1989-10-05 | 1991-05-23 | Unitika Ltd | Manufacture of low temperature heat-sealing polyester film |
| JPH03127945A (en) | 1989-10-12 | 1991-05-31 | Japan Steel Works Ltd:The | Production of tissual film food and apparatus therefor |
| JPH03190709A (en) | 1989-12-21 | 1991-08-20 | Diafoil Co Ltd | Extrusion molding of thermoplastic resin |
| JPH0489841A (en) | 1990-08-03 | 1992-03-24 | Mitsubishi Rayon Co Ltd | Tubular polysaccharide film and its production |
| GB9017800D0 (en) | 1990-08-14 | 1990-09-26 | Unilever Plc | Moisture barrier and its preparation |
| AU9145691A (en) | 1990-11-28 | 1992-06-25 | R.P. Scherer Corporation | High amylose starch substituted gelatin capsules |
| EP0547551B1 (en) | 1991-12-16 | 1997-11-05 | National Starch and Chemical Investment Holding Corporation | Edible films |
| WO1993020110A1 (en) | 1992-03-31 | 1993-10-14 | Parke-Davis & Company | Esterified starch composition |
| US5334640A (en) | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
| NZ244796A (en) | 1992-08-18 | 1995-05-26 | Scherer Corp R P | Capsule shell of soft gelatin contains a medicament and has a removable tab |
| US5451673A (en) | 1993-04-23 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Films fabricated from mixtures of pectin and starch |
| US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
| GB9313329D0 (en) | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| JP3325091B2 (en) | 1993-08-31 | 2002-09-17 | 株式会社トクヤマ | Method for producing porous film |
| JPH07196478A (en) | 1993-12-30 | 1995-08-01 | Hajime Sugii | Soft capsule for highly safe food and medicine |
| US5393054A (en) | 1994-03-09 | 1995-02-28 | Zap Paintball Corporation | Paint ball |
| US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
| GB2298560B (en) | 1994-12-23 | 1998-07-08 | Cpc International Inc | Low-fat cake donuts and process therefor |
| US5656294A (en) | 1995-06-07 | 1997-08-12 | Cibus Pharmaceutical, Inc. | Colonic delivery of drugs |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US5672699A (en) | 1995-09-06 | 1997-09-30 | National Starch And Chemical Investment Holding Corporation | Process for preparation of hydrophobic starch derivatives |
| US5932639A (en) | 1996-05-06 | 1999-08-03 | National Starch And Chemical Investment Holding Corporation | Maltodextrin-based adhesives |
| FI108038B (en) | 1996-06-25 | 2001-11-15 | Polymer Corex Kuopio Ltd Oy | Hydrophobic polymer dispersion and process for its preparation |
| US5726008A (en) | 1996-09-18 | 1998-03-10 | Eastman Kodak Company | Photographic elements with improved vehicles |
| FR2757173A1 (en) | 1996-12-17 | 1998-06-19 | Warner Lambert Co | POLYMERIC COMPOSITIONS OF NON-ANIMAL ORIGIN FOR FILM FORMATION |
| US5976586A (en) | 1997-03-10 | 1999-11-02 | Lawrence Foods | Glaze composition with vegetable gums |
| US6030641A (en) | 1997-06-03 | 2000-02-29 | Uni Colloid Kabushiki Kaisha | Sustained release capsule and method for preparing the same |
| FR2767070B1 (en) | 1997-08-08 | 1999-09-17 | Laurence Paris | AQUEOUS VISCOUS COMPOSITION, LIMPID OR NOT, FOR THE MANUFACTURE OF SOFT CAPSULES AND HARD CAPSULES, AND METHOD FOR MANUFACTURING FILMS FOR SUCH CAPSULES |
| NL1009107C2 (en) | 1997-11-12 | 1999-06-15 | Banner Pharmacaps Inc | Extrusion device for forming multi layer gelatine films used to form soft gel capsules - contains two height adjustable gate valves covering nozzle opening to control thickness of the individual extruded gelatine film layers |
| US6007614A (en) | 1997-12-30 | 1999-12-28 | National Starch And Chemical Investment Holding Corporation | Starch esters as moisture vapor barrier coatings |
| GB9802201D0 (en) * | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
| US5962053A (en) | 1998-02-17 | 1999-10-05 | Viskase Corporation | Edible film and method |
| US6146570A (en) | 1998-03-20 | 2000-11-14 | Rhodia Inc. | Process for producing extruded hydrocolloid granules |
| US6063915A (en) | 1998-07-30 | 2000-05-16 | Hercules Incorporated | Carrageenan compositions and methods for their production |
| US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| PT1117736E (en) | 1998-09-30 | 2004-10-29 | Warner Lambert Co | MODIFIED STARCH MOVIE COMPOSITIONS |
| JP2000127225A (en) | 1998-10-28 | 2000-05-09 | Toshiba Mach Co Ltd | Method and apparatus for controlling operation of twin- screw extruder |
| US6210709B1 (en) | 1999-03-24 | 2001-04-03 | Elementis Specialties, Inc. | Flexible gelatin free encapsulation material useful for pharmaceuticals, paint balls and other formulations |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| ATE291420T1 (en) | 1999-11-19 | 2005-04-15 | Swiss Caps Rechte & Lizenzen | METHOD FOR PRODUCING A MOLDED BODY CONTAINING STARCH, HOMOGENIZED MASS CONTAINING STARCH AND DEVICE FOR PRODUCING A SOFT CAPSULE |
| US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
| US6528088B1 (en) | 2000-06-01 | 2003-03-04 | A. E. Staley Manufacturing Co. | Highly flexible starch-based films |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| DE50012405D1 (en) | 2000-12-20 | 2006-05-11 | Swiss Caps Rechte & Lizenzen | Rotary die method and filling wedge for producing capsules, in particular soft capsules |
| US20020155200A1 (en) | 2000-12-22 | 2002-10-24 | Reg Macquarrie | Edible film formulation |
| DE50015770D1 (en) | 2000-12-29 | 2009-12-03 | Swiss Caps Rechte & Lizenzen | Method and device for producing moldings from a biopolymer material |
| GB2375340B (en) | 2001-05-10 | 2003-09-10 | Croda Int Plc | Gelatin substitute |
| EP1258242A1 (en) | 2001-05-15 | 2002-11-20 | Swiss Caps Rechte und Lizenzen AG | Process of manufacturing shaped bodies, in particular soft capsules |
| US6745546B2 (en) | 2001-11-02 | 2004-06-08 | R.P. Scherer Technologies, Inc. | Encapsulation machine with valved injection wedge |
| US6884060B2 (en) | 2001-11-02 | 2005-04-26 | R.P. Scherer Technologies, Inc. | Apparatus for manufacturing encapsulated products |
-
2002
- 2002-01-18 US US10/051,201 patent/US6949256B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 DE DE60331524T patent/DE60331524D1/en not_active Expired - Lifetime
- 2003-01-15 WO PCT/US2003/001134 patent/WO2003061633A1/en active Application Filing
- 2003-01-15 AT AT03731918T patent/ATE459344T1/en not_active IP Right Cessation
- 2003-01-15 CN CNB038062461A patent/CN100467065C/en not_active Expired - Fee Related
- 2003-01-15 AU AU2003237365A patent/AU2003237365B2/en not_active Expired - Fee Related
- 2003-01-15 EP EP03731918A patent/EP1474115B1/en not_active Expired - Lifetime
- 2003-01-15 CA CA2473312A patent/CA2473312C/en not_active Expired - Fee Related
- 2003-01-15 MX MXPA04006914A patent/MXPA04006914A/en unknown
- 2003-01-15 JP JP2003561578A patent/JP2005529066A/en active Pending
-
2005
- 2005-08-02 US US11/195,372 patent/US20060029660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030138482A1 (en) | 2003-07-24 |
| US20060029660A1 (en) | 2006-02-09 |
| JP2005529066A (en) | 2005-09-29 |
| CN1649572A (en) | 2005-08-03 |
| AU2003237365B2 (en) | 2007-05-31 |
| US6949256B2 (en) | 2005-09-27 |
| EP1474115A1 (en) | 2004-11-10 |
| MXPA04006914A (en) | 2006-03-16 |
| WO2003061633A1 (en) | 2003-07-31 |
| ATE459344T1 (en) | 2010-03-15 |
| DE60331524D1 (en) | 2010-04-15 |
| CN100467065C (en) | 2009-03-11 |
| EP1474115B1 (en) | 2010-03-03 |
| WO2003061633B1 (en) | 2003-12-18 |
| CA2473312A1 (en) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2473312C (en) | Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan | |
| AU2003237365A1 (en) | Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan | |
| US7887838B2 (en) | Non-gelatin film and method and apparatus for producing same | |
| CA2522295C (en) | Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom | |
| CA2341024C (en) | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture | |
| US7816341B2 (en) | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom | |
| US20090208569A1 (en) | Homogeneous, Thermoreversible Alginate Films and Soft Capsules Made Therefrom | |
| EP1496873A2 (en) | Chewable soft capsule | |
| JP2010047548A (en) | Method for producing enteric soft capsule, and enteric soft capsule | |
| ZA200508251B (en) | Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom | |
| US20050019295A1 (en) | Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom | |
| RU2341250C2 (en) | Homogeneous thermal reversible gel film containing cappa-2-carraginan, and soft capsules produced thereof | |
| CN115429771A (en) | Composite glue for capsules and preparation method and application thereof | |
| ZA200508253B (en) | Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180115 |